Yesterday we joined healthcare leaders at the Great Lakes Society of Diabetes & Endocrinology (GLSDE) Annual Meeting in Canandaigua, NY, for educational sessions on treatment for people living with #endocrine disorders. Thank you to the presenters for sharing their expertise.

Living with tumor hyperinsulinism (HI) can mean managing unpredictable and sometimes severe episodes of low blood sugar that may require hospitalization and can delay or interrupt tumor-directed treatment. Swipe to learn about the realities of living with #TumorHI. #RareDisease

Today we announced completion of enrollment in our Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Topline data are expected in mid-December of this year. Learn more: bit.ly/4ylkoyO #TumorHI #Hyperinsulinism #RareDisease #Rezolute

We spent last weekend in Wiltshire, England, with an inspiring community at Insulinoma Charity UK’s Insulinoma (Pilot) Retreat. Rezolute was honored to be a founding partner supporting the program, creating an opportunity for people living with #insulinoma to gather and connect.

In October, we recognize #LiverCancerAwarenessMonth, a time to raise awareness of liver cancer and the serious complications that may occur with some tumors, including persistent or recurring hypoglycemia, known as tumor hyperinsulinism. #TumorHI #Hyperinsulinism #RareDisease

We had a great time at the Giro del Vino classic this weekend, cheering on all the cyclists supporting families affected by #congenitalHI. Thank you to the TnT Cycling Club of New Jersey for hosting the event and choosing @congenitalhi as this year’s beneficiary. #RareDisease

Today we announced FDA's recommendation to hold a pre-BLA meeting as a precursor to submitting a BLA for congenital HI. We are grateful to everyone who has contributed to the sunRIZE program and look forward to advancing toward this important milestone: bit.ly/4hrkVdo

We’re grateful for a week of diving into endocrinology innovation! We connected with leading experts at 3 conferences, including Cleveland Clinic's Intensive Review of Endocrinology and Metabolism, the Western Endocrinology Association Annual Meeting, and SCOPE's Annual Meeting.

At this year’s Pediatric Endocrinologists of the Rocky Mountains (PERM) Conference, #endocrinology experts came together to discuss treatment innovations and the future of patient care. Thank you to everyone who shared their insights and expertise. #CongenitalHI #RareDisease

Today we provided financial results and a business update for fiscal Q4 2026. Read our press release to learn more about recent progress and upcoming milestones as we work to develop a potential treatment for #hyperinsulinism. Learn more: bit.ly/4dyYyjI

Today is #RareCancerDay, a time to highlight the challenges facing patients living with rare cancer, including tumor hyperinsulinism, and raise awareness of the importance of early diagnosis. @RareDiseases is leading the way, sharing real patient stories and helpful resources.

This weekend, we joined endocrinology leaders at the California Association of Clinical Endocrinologists 2026 Endocrine Summit for sessions on emerging therapies shaping the future of endocrine care. Thank you to the organizers for a thoughtful program. #Hyperinsulinism

We’re in New York for the @HCWCO 28th Annual Global Investment Conference and the @MorganStanley Global Healthcare Conference. We’re looking forward to discussing progress and upcoming milestones as we work toward a better treatment option for people living with #hyperinsulinism.

What a week at the European Society for Paediatric Endocrinology (ESPE) Annual Meeting! We're walking away with valuable connections and fresh insights into the latest in endocrinology research, and we're excited to bring these learnings back to our work in #hyperinsulinism.

We’ll be meeting with investors this week at the Cantor Fitzgerald Global Healthcare Conference, sharing updates on our work to advance hyperinsulinism care. Watch our fireside chat today at 3:20 pm ET here: bit.ly/4A7IX4w #Hyperinsulinism #Rezolute

Thank you to @congenitalhi for an unforgettable weekend at the Congenital Hyperinsulinism Family Conference in Marseille, France. We feel fortunate to have the opportunity to hear directly from families living with #congenitalhyperinsulinism and to connect with leading experts.

We're excited to share the latest episode of RARECast, featuring an in-depth conversation with Julie Raskin, CEO of @congenitalhi. Tune in to hear how we can better serve the #CongenitalHI community: bit.ly/4zR58M0 #RareDisease #PatientAdvocacy #Hyperinsulinism

Next week, @congenitalhi will welcome families, clinicians, researchers, advocates, and partners to Marseille, France for a 3-day Congenital Hyperinsulinism Family Conference. Rezolute is honored to support and attend this important event. Learn more: bit.ly/3SvUfyu

New JCEM article: compassionate use outcomes of investigational drug ersodetug in EAP. bit.ly/4coSGZO *𝘌𝘳𝘴𝘰𝘥𝘦𝘵𝘶𝘨 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘳𝘶𝘨 & 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘍𝘋𝘈 𝘰𝘳 𝘢𝘯𝘺 𝘩𝘦𝘢𝘭𝘵𝘩 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘵𝘺

We're headed to the Midwest Endocrinology Society Annual Meeting to connect with leaders across the #endocrinology community. We're looking forward to discussions about advancing #hyperinsulinism care and raising awareness of this #raredisease. Details: bit.ly/45u0tSf